EP0721328A4 - Camptothecin formulations - Google Patents

Camptothecin formulations

Info

Publication number
EP0721328A4
EP0721328A4 EP94929892A EP94929892A EP0721328A4 EP 0721328 A4 EP0721328 A4 EP 0721328A4 EP 94929892 A EP94929892 A EP 94929892A EP 94929892 A EP94929892 A EP 94929892A EP 0721328 A4 EP0721328 A4 EP 0721328A4
Authority
EP
European Patent Office
Prior art keywords
camptothecin formulations
camptothecin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94929892A
Other languages
German (de)
French (fr)
Other versions
EP0721328A1 (en
Inventor
Panayiotis Peri Constantinides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0721328A1 publication Critical patent/EP0721328A1/en
Publication of EP0721328A4 publication Critical patent/EP0721328A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94929892A 1993-09-27 1994-09-27 Camptothecin formulations Withdrawn EP0721328A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12720893A 1993-09-27 1993-09-27
PCT/US1994/010898 WO1995008986A1 (en) 1993-09-27 1994-09-27 Camptothecin formulations
US127208 1998-07-31

Publications (2)

Publication Number Publication Date
EP0721328A1 EP0721328A1 (en) 1996-07-17
EP0721328A4 true EP0721328A4 (en) 1997-09-17

Family

ID=22428860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94929892A Withdrawn EP0721328A4 (en) 1993-09-27 1994-09-27 Camptothecin formulations

Country Status (3)

Country Link
EP (1) EP0721328A4 (en)
JP (1) JPH09504517A (en)
WO (1) WO1995008986A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
AU751439B2 (en) * 1997-09-16 2002-08-15 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
EP1121102B1 (en) * 1998-09-16 2003-04-23 Alza Corporation Liposome-entrapped topoisomerase inhibitors
AU778340B2 (en) * 1999-01-27 2004-12-02 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
DE60115044T2 (en) * 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Liposomal antineoplastic drugs and their uses
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
CA2455170A1 (en) 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
AU2002255810A1 (en) * 2001-03-20 2002-10-03 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
DE10157994A1 (en) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomally encapsulated hydrophobic active ingredients with a high active ingredient content> 50% and methods for producing pharmaceutical preparations which comprise liposomally encapsulated hydrophobic active ingredients
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
DE60335279D1 (en) * 2002-06-26 2011-01-20 Medigene Ag NEW METHOD FOR STABILIZING DIAGNOSTIC AND THERAPEUTIC COMPOUNDS IN A CATIONIC CARRIER SYSTEM
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
EP1629111B1 (en) 2003-05-30 2008-05-28 University Of Chicago Methods and compositions for predicting irinotecan toxicity
WO2005002546A1 (en) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Stabilized topotecan liposomal composition and methods
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
CA2566559C (en) 2004-05-17 2014-05-06 Inex Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
CN100356919C (en) * 2004-05-31 2007-12-26 上海医药工业研究院 Hydroxycamptothecin liposome and its preparation
MXPA06013874A (en) 2004-06-01 2007-04-25 Terumo Corp Irinotecan preparation.
WO2005123078A1 (en) * 2004-06-18 2005-12-29 Terumo Kabushiki Kaisha Liposome preparation containing slightly water-soluble camptothecin
EP1807051A2 (en) * 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
EP1676568A1 (en) * 2004-12-30 2006-07-05 Merckle Gmbh Particles comprising phospholipids, process of preparation and use as medicament
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP2516010A2 (en) 2009-12-23 2012-10-31 Novartis AG Lipids, lipid compositions, and methods of using them
CN102516258B (en) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 Water-soluble vitamin E derivative modified fat-soluble anti-cancer drug compound and preparation, preparation method and application of compound
WO2014015027A1 (en) * 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CN104837483B (en) 2012-11-20 2017-09-01 光谱医药公司 The improved method for preparing the liposome packaged type vincristine of therapeutical uses
MX2015011955A (en) 2013-03-08 2016-04-07 Novartis Ag Lipids and lipid compositions for the delivery of active agents.
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3188760B1 (en) 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
PL439632A1 (en) * 2021-11-23 2023-05-29 Uniwersytet Warszawski Lipid drug carrier, a pharmaceutical formulation, uses thereof and method for producing a lipid drug carrier, a carrier prepared by such method and its applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9508986A1 *

Also Published As

Publication number Publication date
WO1995008986A1 (en) 1995-04-06
EP0721328A1 (en) 1996-07-17
JPH09504517A (en) 1997-05-06

Similar Documents

Publication Publication Date Title
EP0721328A4 (en) Camptothecin formulations
HK1011278A1 (en) Macrolide formulations
IL111004A0 (en) Oral rapamycin formulations
ZA945653B (en) Therapeutic compositions
GB9207832D0 (en) Formulations
GB9325644D0 (en) Novel formulation
ZA946195B (en) Anthelmintic formulations
GB9410252D0 (en) Galenic formulations
GB9214390D0 (en) Formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9311030D0 (en) Pharmaceutical formulations
GB9308622D0 (en) Formulations
GB9306144D0 (en) Formulations
GB9205739D0 (en) Formulations
GB9213271D0 (en) Formulations
GB9224539D0 (en) Formulations
GB9202474D0 (en) Formulations
GB9205738D0 (en) Formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9304799D0 (en) Pharmaceutical formulations
GB9304797D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19970731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000401